Cinfa Middle East

Promoting Access in Healthcare With its expertise in the healthcare sector, Cinfa aims to emphasize the importance of improving patients' quality of life. This includes not only access to effective treatments but also support in prevention and education. The pharmaceutical group is committed by offering affordable, high-quality medicines and collaborating with healthcare professionals and institutions in diverse regions. Its growing presence in the Middle East reflects this dedication to making essential treatments available where they are needed most. As highlighted in Health Magazine, the cardiovascular therapeutics area is one of Cinfa’s major concerns. The company stresses that one of its main R&D focus are medicines to treat and prevent cardiovascular diseases. In line with this preventive vision, Cinfa has strengthened its capacity for innovation and responsiveness through the launch of its new NEO manufacturing plant, a cutting-edge facility conceived under Industry 4.0 principles. This plant integrates, digitizes, and automates all production processes, adapting to the specific needs of each medicine and every stage of its manufacturing, thereby ensuring greater efficiency, quality, and scalability. 📖 Read the full article: https://lnkd.in/dTK98Qvq #CinfaMiddleEast #Accesstohealthcare #CardiovascularHealth #HealthMagazine

Prostate Cancer Management in the Middle East: What You Need to Know A recent study entitled “Prostate Cancer Presentation and Management in the Middle East” by Mutlay Sayan, et al. (2024) provides a comprehensive descriptive analysis of demographic, clinical, and treatment variables with the goal of developing and implementing effective policies. Prostate cancer is one of the most common cancers affecting men worldwide and remains a leading cause of cancer-related morbidity and mortality. According to the study (1,.136 patients), most patients (78%) were diagnosed after developing symptoms rather than through routine prostate-specific antigen (PSA) screening. At the time of diagnosis, 35% of men had clinical T3 or T4 disease, 54% with Stage IV disease and 50% with Gleason score ≥ 8. Regarding treatment, 20% of non-metastatic and 22% of metastatic patients received no treatment. The British Journal of General Practice acknowledges the evidence that in UK higher rates of opportunistic PSA testing reduces diagnosis of metastatic prostate cancer and agrees with testing “higher-than-average" risk men to be tested (black men, men with a family history of prostate cancer and/or men with confirmed genetic risk factor aged > 45 years (2024).   #ProstateCancer #Prevention #PSAScreening #CinfaMiddleEast https://lnkd.in/gnkWFGMp https://lnkd.in/g8MHHRyh

In the context of World Health Day, Cinfa reaffirms its commitment to the research and development of therapeutic solutions and quality treatments that positively impact patients' quality of life. On this day, Cinfa joins all healthcare professionals in the effort to reduce the prevalence of chronic diseases by promoting sustainable health habits, improving access to preventive measures for comprehensive well-being based on scientific evidence, while ensuring the development of quality medicines to treat these diseases. Did you know that up to 80% of non-communicable diseases can be prevented by making small daily lifestyle changes? According to the NCD Alliance. #WorldHealthDay #DiseasesPrevention #CinfaMiddleEast https://lnkd.in/dNnxWFGs

📢 Cinfa’s Stand-Alone Meeting: Key Insights Cinfa has held its first 2025 scientific Stand-Alone Meeting. This series of events brings together leading healthcare professionals and GCC opinion leaders offering a platform for in-depth discussions and updates on the latest advancements in the medical field. 📍 Event Highlights →With a total attendance of 26 participants, this meeting provided a collaborative space for healthcare professionals and opinion leaders to share their expertise and discuss the future of healthcare. →The meeting facilitated an interactive discussion, reviewing real-life case scenarios and enhancing clinical decision-making through audience participation. →Discussions focused on: The evolving challenges and guidelines in Hypertension Management. Rhinogenic Headache: Masked Sinusitis. Medical Treatment of rhino sinusitis and management of antibiotics. 🔑Main Conclusions Dr. Suma Victor Malini, Specialist Cardiologist working in Prime Medical Centre in Dubai, and Dr. Mohamed Elbegermy, Professor of Otolaryngology and Throat Diseases at Cairo University,Egypt, and senior consultant at Ain Shams University in Doha, provided the main messages highlighted during the meeting: →Effective Hypertension Management: Dr. Victor underscored the significance of achieving optimal blood pressure control through the appropriate use of available antihypertensive medications. →Proper Use of Antibiotics: Dr.  Elbegermy emphasized the importance of prescribing antibiotics only when necessary to prevent bacterial resistance. →Accurate Diagnosis of Sinusitis: The doctor also highlighted that many headaches diagnosed as migraines or neuralgias may be caused by sinusitis or nasal septum-turbinate contact. A simple test using local anesthetics and a nasal decongestant can help distinguish between these cases and avoid unnecessary neurological treatments. This meeting reinforces Cinfa’s ongoing commitment to addressing pressing medical challenges and fostering collaboration within the medical community. #CinfaEvents #HealthcareLeadership #HypertensionManagement #InfectiousDiseases #MedicalAdvancements

Anastrozole: A Cost-Effective Option for Postmenopausal Women? A recent study published in BMC Health Services Research (2024) by XiaoXia Wei et al., titled "Anastrozole for the Prevention of Breast Cancer in High-Risk Postmenopausal Women: Cost-effectiveness Analysis in the UK and the USA", concludes that anastrozole—a third-generation aromatase inhibitor—has proven to be cost-effective in reducing breast cancer incidence among high-risk postmenopausal women. This reinforces its potential role as a preventive option, especially in cases where Selective Estrogen Receptor Modulators (SERMs) are contraindicated. The findings suggest that although anastrozole increases healthcare costs, it significantly improves outcomes by reducing breast cancer risk and enhancing quality-adjusted life-years (QALYs) compared to no prevention. Interestingly, the longer the model’s cycle, the greater its acceptability, making this option even more compelling for long-term use. These results offer valuable insights for clinicians and patients when making evidence-based decisions on preventive treatments. Moreover, they provide critical data for national health policymakers to develop scientifically sound strategies in cancer prevention. Ultimately, anastrozole stands out as a well-suited option for high-risk postmenopausal women. Maximizing its benefits requires ongoing patient monitoring and adherence to therapy, ensuring optimal outcomes and minimizing potential risks. #Anastrozole #BreastCancer #CancerPrevention #CinfaMiddleEast https://lnkd.in/dMwgqiZ7

Pandemic of Coronary Heart Disease A review about “The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What clinicians Need to Know” by Yosef Manla and Wael Almahmeed, published on Springer (2023), provides quality information on the prevalence of Coronary Heart Disease (CHD) in the MENA region, highlighting regional patient characteristics, clinical challenges and future directions to optimize CHD care in the region. Key Findings: →The region exhibits the highest age-adjusted rates of CHD in the Global Burden of Disease (GBD) study. CHD contributed the most to the number of incident cases of cardiovascular disease (58%). →Common risk factors: metabolic (high systolic blood pressure, high LDL cholesterol, high fasting plasma glucose, high body mass index and kidney dysfunction), behavioral (dietary risks, tobacco, and low physical activity), and environmental (air pollution and non-optimal temperature). →Patients in MENA experience their first Myocardial Infarction (MI) at least 10 years younger than their Western counterparts and the proportion of individuals aged ≤40 years presenting with MI in the MENA was three times higher. →Women with CHD in the MENA have a higher burden of CVD risk factors and worse clinical outcomes. Clinical practice implications: →Patients benefit from a multidisciplinary cardiometabolic clinic model of care where cardio-preventive and weight-loss medications, behavioral counseling, diet and lifestyle interventions are all provided at once.   Avoid delays in seeking health care to properly treat patients. Develop and execute strategies aimed at addressing the burden of coronary heart disease in the MENA region.   #Cardiology #CoronaryHeartDisease #CinfaMiddleEast https://lnkd.in/d44ZBSc2

Hypertonic Saline Sprays: Evaluation and Effectiveness An article entitled “Real-World Evaluation of the Safety and Effectiveness of 2.3% Hypertonic Saline Soft Mist Spray for Sino-Nasal Symptoms” by Dipak Ghandi et al. (2024), provides relevant data on the efficacy of the use of 2.3% hypertonic saline soft mist spray, which results have shown to improve symptoms of nasal congestion and rhinorrhea in patients with sino-nasal conditions. Key findings: →The spray is well-tolerated and effective in patients with sino-nasal symptoms in real-world clinical settings. → Nasal saline washes disrupt the viscous surface layer and remove mucus along with particulate material embedded in it, while increasing hydration, boosting the underlying ciliary beat frequency and decreasing local inflammatory mediators.   Clinical conclusions: →The use of a hypertonic saline soft mist spray is considered an adjunct for managing mild to moderate sino-nasal symptoms, such as nasal congestion, rhinorrhea and waking up during the night. →At baseline, 80% of patients (104/130) were prescribed co-medications while only 48.4% (63/130 patients) were prescribed co-medications at follow-up, suggesting a 39% reduction in the use of co-medications with the use of adjuvant 2.3% hypertonic saline. →The hypertonic saline relieved sinonasal symptoms by 50% in 3.27 ± 1.07 days, which shows the efficacy of hypertonic saline nasal irrigation (HSNI). →The study concluded that using hypertonic nasal saline regularly for four weeks in patients with allergic rhinitis is safe and more effective than 0.9% isotonic saline in relieving congestion and enhancing quality of life scores. The hypertonic saline spray also showed a reduction in the use of antihistamines in these patients.   #HypertonicSalineSprays #AllergicRhinitis #SeaSaltSaline #CinfaMiddleEast https://lnkd.in/dNMGxAQN -symptoms#!

Pre-eclampsia in the Middle East: Key Insights on Prevalence, Risk factors and Healthcare strategies An article titled “Prevalence of Pre-eclampsia in Women in the Middle East: A Scoping Review” by Aytullah Hegazy et al. published in Frontiers in Public Health (2024) discusses Pre-eclampsia as a hypertensive disorder during pregnancy that is the second most common cause of maternal deaths worldwide. Metabolic syndrome is recognized as one of the risk factors for pre-eclampsia. This finding raises the possibility that the prevalence of pre-eclampsia in the region may also be higher compared with global estimates. The aim of his scoping review of the literature is to investigate the nature and extent of studies evaluating the prevalence of pre-eclampsia within the Middle East region. A notable rise in the prevalence of metabolic syndrome has been observed among the young population in the United Arab Emirates, surpassing global prevalence estimates. This raises the possibility that women from the Middle East may experience a higher prevalence of pre-eclampsia, given that pre-eclampsia is linked to compromised maternal metabolic and cardiovascular function. Identified risk factors include metabolic syndrome, advanced maternal age, obesity, and a history of hypertension, emphasizing the importance of targeted interventions for at-risk populations. These findings underscore a pressing requirement for additional research, given the higher prevalence of metabolic risk factors and the possibility that they are currently underestimated. This is particularly significant for enhancing awareness among both the population and healthcare providers, which could lead to improved prenatal care protocols. Regular blood pressure monitoring and comprehensive metabolic assessments are crucial to mitigate the risks associated with pre-eclampsia. This review serves as a crucial resource for healthcare professionals and policymakers aiming to enhance maternal health outcomes in the Middle East. Implementing the recommended protocols could lead to significant reductions in pre-eclampsia-related complications.   #Gynecology #MaternalHealth #PreEclampsia #CinfaMiddleEast https://lnkd.in/d9Kd22t3

Unveiling Fibromyalgia: Key Symptoms and Diagnostic Insights The articles entitled “Prevalence of fibromyalgia syndrome in Saudi Arabia: A Systematic Review and Meta-analysis” by Yasser Bawazir and “Is middle East pain syndrome (MEPS) a variant of fibromyalgia syndrome or a distinct disease” published in BMC Musculoskeletal (2024), conduct a systematic review and meta-analysis to estimate the prevalence of fibromyalgia syndrome and present valuable information  about a newly described disorder called Middle East Pain Syndrome (MESPS). Key Findings: →Prevalence:  Fibromyalgia Syndrome (FMS) affects 13.4% of the Saudi Arabian population. →Common Symptoms:  widespread pain, fatigue, mood disturbances, and cognitive impairment. →A recently identified syndrome resembles rheumatoid arthritis (RA) characterized by fibromyalgia, secondary hyperparathyroidism, and a chronic vitamin D3 deficit. It is an illness brought on by heavy metal contamina­tion, including lead and cadmium. Then after, this syn­drome is named Middle East Pain Syndrome (MEPS) because it was first described in the Middle East. This was ascribed to many factors such as indulgence in fizzy waters, smoking, fried snacks, which all were reported to be polluted with lead and cadmium. →Elevated IL-17 levels, non-scleroderma pattern capillaroscopic and enthesopathy findings in both MEPS and FMS patients are strongly supportive that inflammatory mechanisms participate in the pathogenesis of both diseases. →The significant increase of these findings in MEPS than FMS patients as well as the presence of hand tufts spur-like excrescences, confirm that the newly discovered MEPS is a different disease although it involves fibromyalgia symptoms and signs. Clinical Recommendations: →Assess vitamin D levels and inflammatory markers in suspected fibromyalgia cases to differentiate between FMS and MEPS. → A higher IL-17 levels, advanced imaging and capillaroscopic patterns can aid in accurate diagnosis, ensuring tailored treatment strategies. These researches underscores the importance of precise diagnostics in chronic pain syndromes. Differentiating MEPS from FMS can prevent misdiagnosis, guide effective treatments, and improve patient outcomes. #GestationalDiabetes #MaternalHealth #GDM #CinfaMiddleEast https://lnkd.in/dFB2gYWN https://lnkd.in/d9t2T8AR

🌙 Ramadan Mubarak from Cinfa Cinfa extends its warmest wishes to all of you and your loved ones for prosperity and good health. Ramadan Kareem. #RamadanMubarak #RamadanKareem